Percentage return on R&D among mid cap biopharma companies 2013-2020

Published by
Matej Mikulic,
Nov 7, 2022
This statistic shows the percentage of return on investments in research and development among mid cap biopharmaceutical companies from 2013 to 2020. Within this time period, the returns declined from 17.4 percent to 5.2 percent in 2019. In 2020. returns increased slightly to 6.6 percent.

Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020

Loading statistic...

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

2021

Region

Worldwide

Survey time period

2013 to 2020

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Medical biotech industry "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Medical biotech industry

Global overview

7

U.S. and European landscape

6

Focus: U.S. companies

8

Research & development

6

Products

5

Funding/M&A/IPOs

6

Focus: RNA/mRNA

4

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Biotech drugsGlobal pharmaceutical industryCancer in the U.S.AmgenCoronavirus (COVID-19) vaccines and treatments
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu